Compare Microsoft (MSFT) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs Novo Nordisk A/S — how do they compare? Microsoft trades at $531.78 (market cap $3.88T), while Novo Nordisk A/S trades at $38.44 (market cap $165.31B). The key difference: Microsoft is far larger — about 23.5× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Microsoft for 142 Days and Novo Nordisk A/S for 116 Days on average.
| MSFT | NVO | |
|---|---|---|
Market Cap | $3.88T | $165.31B |
Volume | 19,593,392 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $542.07 | $63.98 |
52-Week Low | $352.83 | $35.29 |
Typical Hold Time | 142 Days | 116 Days |
Enterprise Value | $3.86T | $179.56B |
Dividend Yield | 0.75% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft trades at $529.76, up 0.09% with strong bullish technical signals and consistent earnings beats. The company maintains robust fundamentals with $281.72B revenue, 40.31% net margin, and positive cash flow. Recent analyst coverage shows 82% buy ratings with a $571.76 consensus target, while technical indicators suggest support at $526 and resistance at $533.
Outlook remains positive with AI leadership driving growth, though elevated P/E of 29.11 and competitive pressures present risks. The stock offers solid dividend income and institutional support, but investors should monitor capital expenditure trends and market rotation away from mega-cap tech stocks.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
